|
Brand Safety Leader 2
| Details |
Country: USA
Location: New Jersey-Northern East hanover, NJ 07936
Total applied: 40 |
|
Brand Safety Leader 2
Welcome to Novartis - the company that considers its employees to be its greatest asset. Good Business. Great Opportunities. How do you spend your day? Are you passionate about what you do? At Novartis, our focus is clear, our purpose defined. We're part of a team that's making a difference in the quality of people's lives.Think What's Possible.A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented, performance driven people. All of which makes us the most rewarding employer in our field.We are looking for a Brand Safety Leader responsible for safety issue management from end of Phase I (POC) through Life Cycle Management.Responsible for overall signal detection,monitoring,evaluation,interpretation and appropriate management of safety information, based on information from all relevant line functions, postmarketing data, and other sources. Develops and updates, at milestones, the safety profiling and risk management plan from end of Phase I (POC) through Life Cycle Management as relevant.Leads IPT Safety Subteam. Serves as safety representative on International Clinical Team (and IPT).Manages Drug Safety Monitoring Board activities for assigned projects/products, as required.Responsible for initial development and updates of safety information in Basic Prescribing Information (core global labeling),including addressing safety issues optimally in all project/product labeling claims. Responsible for responses to inquires from regulatory authorities or health care professionals on safety issues. Prepares safety data for health authority review boards. Responsible for responses to legal queries and CPO requests involving safety issues. Ensures safety information communicated to EU Qualified Person in a timely fashion.Provides integrated safety input into all regulatory documents required during active developmentReviews and provides integrated safety input into clinical study protocols and clinical study reports, including Brand Optimization studiesCo-ordinates involvement of external experts (e.g. authors of "white papers", members of trial-specific data safety monitoring boards, ad-hoc support for HA meetings, etc.)Prepares and may present brand safety issues to internal Novartis Boards and other meetingsProvides relevant input for IPT, ICT and TA Expert Panel meetings, as needed Collaborates productively with colleagues from Clinical Research, Drug Regulatory Affairs, Medical Affairs, Medical Information, Statistics, Safety Data Management, Epidemiology and other related departments.Provides support as needed for licensing activities, regulatory authority inspections and for project/product recall activities.Serves as and performs activities of Pharmacovigilance Leader as needed.QualificationsEducation (minimum/desirable): Medical degree required, Specialty Board certification desirable. Useful additional degrees: Post graduate degree in Pharmaceutical Medicine; Master of Public Health in Epidemiology (or equivalent)Languages: Fluent in spoken and written English, Understanding in another language (e.g. French, German, Spanish) desirable.3 years clinical experience postdoctoral· At least 5 years are in drug development in a major pharmaceutical company (of which 2 years in a global position), including 2 years in safety at an operational or medical position- · Experience in preparing or contributing to preparation of clinical safety assessments and regulatory re-ports/submissions involving safety information.· Experience in leading cross-functional, multi-cultural teams· Experience with (safety or others) issue management· Experience in drug development, clinical trial method-ology, regulatory requirements, scientific methodology, statistics and writing of publications Novartis is committed to embracing and leveraging diverse backgrounds. Novartis is an equal opportunity employer M/F/D/V.To apply for this position, Click HereTo learn about other Novartis opportunities, Click Here Link to Novartis Pharmaceuticals opportunities Send this Job to a Friend EEO Novartis is committed to embracing and leveraging diverse backgrounds. Novartis is an equal opportunity employer M/F/D/V.
|
| Related jobs |
|
|
Manager, Demand Planning
Schering-Plough is an innovation-driven, science-centered global health care company. Through our own biopharmaceutical research and collaborations with partners, we ...
|
|
|
Operations Manager, Manufacturing (Triathlon Femoral)
Stryker is an exceptional company with exceptional people who deliver exceptional results. We have differentiated ourselves by responding in innovative ways to the needs ...
|
|
|
Manager, Field Sales Analytics - (Job Number: 0809307)
Sales/Retail/Business Development Reference Code: 710314 ...
|
|
|
Supply Chain Planner - FUZE
Company: Coca Cola Company Job Category: Logistics/Transportation Location: Englewood Cliffs, NJ 07632 Status: Full Time, Employee Career Level: Experienced (Non-M...
|
|
|
Senior Fellow
Welcome to Novartis - the company that considers its employees to be its greatest asset. Good Business. Great Opportunities. How do you spend your day? Are you ...
|
|
|
Submission Coordinator
Welcome to Novartis - the company that considers its employees to be its greatest asset. Good Business. Great Opportunities. How do you spend your day? Are you ...
|
|
|
Clinical Data Managers (All Levels)
"I like Cmed's flexibility in approach and the variety, challenge and responsibility in my job. Cmed has a friendly atmosphere. I really feel part of the team, that my ...
|
|
|
Associate Director Regulatory Affairs CMC
Associate Director, Regulatory Affairs, CMC
Responsibilities include:
Directing the RA strategy in support of IND developmentWorking on international ...
|
|
|
Oracle Reports Developer (JJ)
FOR IMMEDIATE CONSIDERATION PLEASE SEND YOUR RESUME TO JOHN.JORDAN@MODIS.COM .Major Modis client based in Central New Jersey has an immediate need for a Oracle Reports D...
|
|
|
PM/Sr. Product Management, CML & GIST Alliances
Welcome to Novartis - the company that considers its employees to be its greatest asset. Good Business. Great Opportunities. How do you spend your day? Are you ...
|
|
| Related press releases |
Courageous reform
There can be little doubt we are making progress when it comes to improving further education. More young people and adults than ever are gaining good qualifications ever...
|
|
Half of MG Rover workers want to return
Almost a year after the collapse of MG Rover, many former workers are paid less and wish they still worked for the firm, according to a report released today.
Of the nea...
|
|
Making ends meet
Earning some dosh to get through uni might seem unavoidable, but don't lose sight of the reason you are there: to get a degree. Earning shouldn't mean missing vital lectu...
|
|
|
|
The earth man cometh
I am merely the conduit,' says Patrick Holden, director of the Soil Association, when I ask him to sum up his achievement after 10 years in the job. 'The great thinkers, ...
|
|
Battle at the coalface
In his television review Rupert Smith described the NUM miners leader Arthur Scargill as "a ghastly little man who needed to be trodden on" (G2, March 23). I suppose he w...
|
|
Hutton eases small firms' pension fears
The government will not force employers to contribute to workers' pensions without making efforts to minimise the impact on firms, the work and pensions secretary, John H...
|
|
NHS hospital redundancies gather pace
A wave of redundancies across the NHS in England gathered force yesterday when a London teaching hospital announced that nearly 500 posts will be axed in an attempt to di...
|
|
Union warning over 'raw' stalls handlers
The Transport and General Workers Union (T&G) yesterday launched a fierce attack on the overall standard of the stalls handlers likely to be working at British racecourse...
|
|
Minimum wage to rise to £5.35
The minimum wage will rise by 6% in October to £5.35, the government confirmed yesterday, but it cautioned that the days of big, inflation-beating rises may be over...
|
|
|
|